The benefits of a diet high in fiber and yogurt have already been established for cardiovascular disease and gastrointestinal cancer. The new findings, based on an analysis of data from studies involving 1.4 million adults in the United States, Europe, and Asia, suggest this diet may also protect against lung cancer. Researchers divided participants into...
Tag: <span>Lung cancer</span>
Post
High fiber, yogurt diet associated with lower lung cancer risk
VANDERBILT UNIVERSITY MEDICAL CENTER A diet high in fiber and yogurt is associated with a reduced risk for lung cancer, according to a study by Vanderbilt University Medical Center researchers published in JAMA Oncology. IMAGE: SENIOR AUTHOR XIAO-OU SHU, MD, PHD, MPH, INGRAM PROFESSOR OF CANCER RESEARCH, ASSOCIATE DIRECTOR FOR GLOBAL HEALTH AND CO-LEADER OF...
Post
Secrets of lung cancer spread found in patients’ blood and biopsies
by Cancer Research UK Early signs that a patient’s lung cancer may spread and become untreatable can be picked up in samples of their blood and tumour, according to a trio of papers published in Nature Medicine today. The three studies are all part of Cancer Research UK’s £14million TRACERx project, which aims to understand...
Post
Screening for lung cancer based on risk could save lives
by Andrea Laferle, University of Michigan Changing the way individuals are selected to be screened for lung cancer, by considering their probability of getting or dying from lung cancer calculated from risk-prediction models, could prevent 14 percent of lung cancer deaths per year. The Cancer Intervention and Surveillance Modeling Network Lung Working Group (CISNET), which...
Post
Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer
Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase 1B study UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON — Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer....
Post
Electronic nose can sniff out which lung cancer patients will respond to Immunotherapy
by European Society for Medical Oncology An electronic nose that detects chemicals in the breath of lung cancer patients can identify with 85% accuracy those who will or will not respond to immunotherapy, according to new research published in the leading cancer journal Annals of Oncology today. The results of the first study to investigate this...
Post
Lung cancer screening model favored in Europe detects more cancers than 1 preferred in the US
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Barcelona–Researchers reported today that a prospective trial comparing two screening methods for at-risk lung cancer patients found that a model used by Canadian, Australian and European public health organizations detected more cancers than the screening model used by the United States Preventive Services Task Force (USPSTF). The...
Post
Major gaps exist in patient understanding of genomic test results, Lung-MAP study shows
by SWOG Cancer Research Network A majority of cancer patients don’t understand key aspects of the genomic test results they receive as participants in biomarker-driven clinical trials, according to a first-of-its-kind pilot study conducted under the Lung Cancer Master Protocol (Lung-MAP). In a September 9 presentation at the World Conference on Lung Cancer in Barcelona,...
Post
The test that could save the life of long-time smokers
by Richard Gunderman, The Conversation A test called CT lung cancer screening could save the lives of tens of thousands of American smokers and former smokers every year, but only only 4% of those eligible are getting it. One such patient, a 58-year-old woman I’ll call Marie, battled cigarette smoking for over three decades before...
Post
Dacomitinib in advanced lung cancer: Disadvantages outweigh survival advantage
by Institute for Quality and Efficiency in Health Care Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether...